Rchr
J-GLOBAL ID:201601014826682536   Update date: Apr. 06, 2024

Oyanagi Jun

オヤナギ ジュン | Oyanagi Jun
Research field  (1): Tumor biology
Research theme for competitive and other funds  (3):
  • 2021 - 2024 Elucidation of synergistic mechanisms in the combination of chemotherapy and PD-1/L1 inhibitors and exploration for novel therapeutic targets
  • 2019 - 2022 ヒト肺がんオルガノイドを用いたプレシジョンメディシンに向けた基盤研究
  • 2016 - 2018 Role of Kras mutations in intestinal tumor progression
Papers (36):
  • Mai Kato, Daichi Fujimoto, Takahiro Kaki, Eri Takase, Takeya Sugimoto, Ryota Shibaki, Shunsuke Teraoka, Atsushi Hayata, Hiroaki Akamatsu, Masanori Nakanishi, et al. Adjacent angle size correlates with diagnostic sensitivity of endobronchial ultrasonography with a guide sheath. Journal of thoracic disease. 2023. 15. 11. 6019-6028
  • Eri Takase, Hiroaki Akamatsu, Shunsuke Teraoka, Keita Nakaguchi, Masanori Tanaka, Takahiro Kaki, Katsuyuki Furuta, Koichi Sato, Eriko Murakami, Takeya Sugimoto, et al. A Phase II Study of High-Flow Nasal Cannula for Relieving Dyspnea in Advanced Cancer Patients. Journal of pain and symptom management. 2023
  • Yuichi Ozawa, Nobuyuki Yamamoto, Kouji Yamamoto, Kentaro Ito, Hirotsugu Kenmotsu, Hidetoshi Hayashi, Takehito Shukuya, Daichi Fujimoto, Shunichi Sugawara, Seiji Niho, et al. Creation of an Integrated Clinical Trial Database and Data Sharing for Conducting New Research by the Japan Lung Cancer Society. Japanese Journal of Lung Cancer. 2023. 63. 3. 161-181
  • Ryota Shibaki, Yuichi Ozawa, Susumu Noguchi, Yusuke Murakami, Eri Takase, Yuichiro Azuma, Masaru Maebeya, Takeya Sugimoto, Atsushi Hayata, Takahiro Hayakawa, et al. Impact of pre-existing interstitial lung abnormal shadow on lung injury development and severity in patients of non-small cell lung cancer treated with osimertinib. Cancer medicine. 2022. 11. 20. 3743-3750
  • Masanori Tanaka, Daichi Fujimoto, Hiroaki Akamatsu, Hiromitsu Sumikawa, Nobuyuki Yamamoto. Radiographic findings useful for diagnosis of primary chest wall lymphoma without preceding pleural disease: A case report. Respirology case reports. 2022. 10. 9. e01019
more...
MISC (12):
  • 小柳 潤, 洪 泰浩, 佐藤 孝一, 杉本 武哉, 柴木 亮太, 寺岡 俊輔, 藤本 大智, 徳留 なほみ, 早田 敦志, 小澤 雄一, et al. Establishment of organoids derived from patients with advanced thoracic malignancies(和訳中). 肺癌. 2021. 61. 6. 682-682
  • 小澤 雄一, 春谷 勇平, 小柳 潤, 村上 恵理子, 赤松 弘朗, 早田 篤志, 上田 弘樹, 中西 正典, 洪 泰浩, 山本 信之. CD24及びCD47腫瘍発現とPD-1/L1阻害剤の有効性及び投与後サイトカイン変動との関連. 和歌山医学. 2021. 72. 1. 42-42
  • 小柳 潤, 洪 泰浩, 佐藤 孝一, 赤松 弘朗, 上田 弘樹, 山本 信之. 進行非小細胞肺癌患者における免疫チェックポイント阻害剤治療の臨床効果予測バイオマーカーの探索. 日本癌学会総会記事. 2020. 79回. OJ12-1
  • 小柳 潤, 洪 泰浩, 佐藤 孝一, 寺岡 俊輔, 徳留 なほみ, 早田 敦志, 赤松 弘朗, 小澤 雄一, 中西 正典, 上田 弘樹, et al. 免疫チェックポイント阻害薬で治療した進行性NSCLCにおける血清タンパク質の複合分析(Combined analysis of serum proteins in advanced NSCLC treated with immune checkpoint inhibitors). 肺癌. 2020. 60. 6. 532-532
  • 小柳 潤, 洪 泰浩, 寺岡 俊輔, 金井 一修, 早田 敦志, 赤松 弘朗, 小澤 雄一, 赤松 啓一郎, 中西 正典, 上田 弘樹, et al. Pembrolizumabにて治療した進行NSCLC患者における予測因子としての血清タンパク質レベル(Predictive Values of Serum Protein Levels in Advanced NSCLC Patients Treated with Pembrolizumab). 肺癌. 2019. 59. 6. 709-709
more...
Lectures and oral presentations  (13):
  • Establishment of organoids derived from patients with advanced thoracic malignancies
    (2021)
  • Establishment of organoids derived from patients with advanced thoracic malignancies
    (2021)
  • Combined analysis of serum proteins in advanced NSCLC treated with immune checkpoint inhibitors
    (2020)
  • Combined analysis of serum protein levels in advanced NSCLC patients treated with immune checkpoint inhibitors
    (2020)
  • Predictive Values of Serum Protein Levels in Advanced NSCLC Patients Treated with Pembrolizumab
    (2019)
more...
Education (2):
  • 2010 - 2013 Yokohama City University Graduate Graduate School of Nanobioscience
  • 2008 - 2010 Yokohama City University Graduate
Professional career (1):
  • 博士(理学) (横浜市立大学)
Work history (3):
  • 2021/04 - 2022/07 Wakayama Medical University
  • 2017/04 - 2021/03 Wakayama Medical University
  • 2013/04 - 2017/03 Japanese Foundation for Cancer Research
Association Membership(s) (4):
THE JAPAN LUNG CANCER SOCIETY ,  Japanese Society of Medical Oncology ,  American Association for Cancer Research ,  THE JAPANESE CANCER ASSOCIATION
※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page